To include your compound in the COVID-19 Resource Center, submit it here.

Eravacycline: Interim Phase III data

Interim data from 143 patients with cUTI in the lead-in portion of the 2-part, double-blind, double-dummy, international Phase III IGNITE 2 trial showed that both IV-to-oral dosing regimens of eravacycline compared "favorably" to levofloxacin on the FDA- and EMA-defined primary endpoints. Tetraphase said the lead-in

Read the full 451 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers